Conversion Surgery in Pancreatic Cancer View Full Text


Ontology type: schema:Chapter     


Chapter Info

DATE

2021-07-20

AUTHORS

Akio Saiura

ABSTRACT

Unresectable pancreatic ductal adenocarcinoma (UR-PDAC) is divided into metastatic PDAC (mPDAC) and locally advanced PDAC (LA-PDAC). Conversion surgery (CS) has been gaining more attention due to the advent of effective systemic chemotherapy and surgical innovation of pancreatectomy with vascular resection and reconstruction. A significant improvement in overall survival has been reported in retrospective and prospective cohort studies. However, there are no robust data which indicate the clear benefit of CS and no consensus of the indication and optimal timing of CS for initially unresectable pancreatic cancer. Several prospective clinical trials are ongoing to clarify the benefit of CS for UR-PDAC. More... »

PAGES

83-94

Book

TITLE

Management of Pancreatic Cancer and Cholangiocarcinoma

ISBN

978-981-16-2869-6
978-981-16-2870-2

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/978-981-16-2870-2_8

DOI

http://dx.doi.org/10.1007/978-981-16-2870-2_8

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1139801657


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Hepatobiliary-Pancreatic Surgery, Juntendo University School of Medicine, Hongo, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.258269.2", 
          "name": [
            "Department of Hepatobiliary-Pancreatic Surgery, Juntendo University School of Medicine, Hongo, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Saiura", 
        "givenName": "Akio", 
        "id": "sg:person.0612301703.87", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0612301703.87"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2021-07-20", 
    "datePublishedReg": "2021-07-20", 
    "description": "Unresectable pancreatic ductal adenocarcinoma (UR-PDAC) is divided into metastatic PDAC (mPDAC) and locally advanced PDAC (LA-PDAC). Conversion surgery (CS) has been gaining more attention due to the advent of effective systemic chemotherapy and surgical innovation of pancreatectomy with vascular resection and reconstruction. A significant improvement in overall survival has been reported in retrospective and prospective cohort studies. However, there are no robust data which indicate the clear benefit of CS and no consensus of the indication and optimal timing of CS for initially unresectable pancreatic cancer. Several prospective clinical trials are ongoing to clarify the benefit of CS for UR-PDAC.", 
    "editor": [
      {
        "familyName": "Isayama", 
        "givenName": "Hiroyuki", 
        "type": "Person"
      }, 
      {
        "familyName": "Nakai", 
        "givenName": "Yousuke", 
        "type": "Person"
      }, 
      {
        "familyName": "Sasaki", 
        "givenName": "Takashi", 
        "type": "Person"
      }
    ], 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/978-981-16-2870-2_8", 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-981-16-2869-6", 
        "978-981-16-2870-2"
      ], 
      "name": "Management of Pancreatic Cancer and Cholangiocarcinoma", 
      "type": "Book"
    }, 
    "keywords": [
      "conversion surgery", 
      "metastatic PDAC", 
      "pancreatic cancer", 
      "unresectable pancreatic ductal adenocarcinoma", 
      "unresectable pancreatic cancer", 
      "prospective cohort study", 
      "prospective clinical trials", 
      "effective systemic chemotherapy", 
      "pancreatic ductal adenocarcinoma", 
      "advanced PDAC", 
      "UR-PDAC", 
      "systemic chemotherapy", 
      "vascular resection", 
      "overall survival", 
      "cohort study", 
      "ductal adenocarcinoma", 
      "clinical trials", 
      "optimal timing", 
      "surgical innovation", 
      "surgery", 
      "robust data", 
      "cancer", 
      "clear benefit", 
      "PDAC", 
      "significant improvement", 
      "pancreatectomy", 
      "resection", 
      "chemotherapy", 
      "adenocarcinoma", 
      "trials", 
      "survival", 
      "benefits", 
      "indications", 
      "consensus", 
      "study", 
      "timing", 
      "improvement", 
      "more attention", 
      "reconstruction", 
      "data", 
      "advent", 
      "attention", 
      "innovation"
    ], 
    "name": "Conversion Surgery in Pancreatic Cancer", 
    "pagination": "83-94", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1139801657"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/978-981-16-2870-2_8"
        ]
      }
    ], 
    "publisher": {
      "name": "Springer Nature", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/978-981-16-2870-2_8", 
      "https://app.dimensions.ai/details/publication/pub.1139801657"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2022-11-24T21:14", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/chapter/chapter_230.jsonl", 
    "type": "Chapter", 
    "url": "https://doi.org/10.1007/978-981-16-2870-2_8"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/978-981-16-2870-2_8'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/978-981-16-2870-2_8'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/978-981-16-2870-2_8'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/978-981-16-2870-2_8'


 

This table displays all metadata directly associated to this object as RDF triples.

112 TRIPLES      22 PREDICATES      67 URIs      60 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/978-981-16-2870-2_8 schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author Nafb2457b74b849b1bceb53dd8dd8a728
4 schema:datePublished 2021-07-20
5 schema:datePublishedReg 2021-07-20
6 schema:description Unresectable pancreatic ductal adenocarcinoma (UR-PDAC) is divided into metastatic PDAC (mPDAC) and locally advanced PDAC (LA-PDAC). Conversion surgery (CS) has been gaining more attention due to the advent of effective systemic chemotherapy and surgical innovation of pancreatectomy with vascular resection and reconstruction. A significant improvement in overall survival has been reported in retrospective and prospective cohort studies. However, there are no robust data which indicate the clear benefit of CS and no consensus of the indication and optimal timing of CS for initially unresectable pancreatic cancer. Several prospective clinical trials are ongoing to clarify the benefit of CS for UR-PDAC.
7 schema:editor Nbe8c37f537d84b7cb4490edb5605fef3
8 schema:genre chapter
9 schema:isAccessibleForFree false
10 schema:isPartOf Nb54f97420a10489db04e26c8caff94e5
11 schema:keywords PDAC
12 UR-PDAC
13 adenocarcinoma
14 advanced PDAC
15 advent
16 attention
17 benefits
18 cancer
19 chemotherapy
20 clear benefit
21 clinical trials
22 cohort study
23 consensus
24 conversion surgery
25 data
26 ductal adenocarcinoma
27 effective systemic chemotherapy
28 improvement
29 indications
30 innovation
31 metastatic PDAC
32 more attention
33 optimal timing
34 overall survival
35 pancreatectomy
36 pancreatic cancer
37 pancreatic ductal adenocarcinoma
38 prospective clinical trials
39 prospective cohort study
40 reconstruction
41 resection
42 robust data
43 significant improvement
44 study
45 surgery
46 surgical innovation
47 survival
48 systemic chemotherapy
49 timing
50 trials
51 unresectable pancreatic cancer
52 unresectable pancreatic ductal adenocarcinoma
53 vascular resection
54 schema:name Conversion Surgery in Pancreatic Cancer
55 schema:pagination 83-94
56 schema:productId N1a2aa8cfeda64e319b922e1ae96d5934
57 N44e72f4b0aca4192916296aabd81527d
58 schema:publisher N4f21d33bacac4fbfb27e901fe232e8eb
59 schema:sameAs https://app.dimensions.ai/details/publication/pub.1139801657
60 https://doi.org/10.1007/978-981-16-2870-2_8
61 schema:sdDatePublished 2022-11-24T21:14
62 schema:sdLicense https://scigraph.springernature.com/explorer/license/
63 schema:sdPublisher Nb458219e7acc4dd3a6895abe0bfbf7a5
64 schema:url https://doi.org/10.1007/978-981-16-2870-2_8
65 sgo:license sg:explorer/license/
66 sgo:sdDataset chapters
67 rdf:type schema:Chapter
68 N1a2aa8cfeda64e319b922e1ae96d5934 schema:name doi
69 schema:value 10.1007/978-981-16-2870-2_8
70 rdf:type schema:PropertyValue
71 N3ad09f1fa2434e8092a6255c1f901d0f rdf:first N608af0390993497db155b76ed70cacbd
72 rdf:rest rdf:nil
73 N40a93706a0e245ad8058ea568bf4aa13 schema:familyName Nakai
74 schema:givenName Yousuke
75 rdf:type schema:Person
76 N44e72f4b0aca4192916296aabd81527d schema:name dimensions_id
77 schema:value pub.1139801657
78 rdf:type schema:PropertyValue
79 N4f21d33bacac4fbfb27e901fe232e8eb schema:name Springer Nature
80 rdf:type schema:Organisation
81 N50533a6c84764606ac88cae5cc0a1e8d schema:familyName Isayama
82 schema:givenName Hiroyuki
83 rdf:type schema:Person
84 N608af0390993497db155b76ed70cacbd schema:familyName Sasaki
85 schema:givenName Takashi
86 rdf:type schema:Person
87 N8caf25440b04494a96d1b6db35457c43 rdf:first N40a93706a0e245ad8058ea568bf4aa13
88 rdf:rest N3ad09f1fa2434e8092a6255c1f901d0f
89 Nafb2457b74b849b1bceb53dd8dd8a728 rdf:first sg:person.0612301703.87
90 rdf:rest rdf:nil
91 Nb458219e7acc4dd3a6895abe0bfbf7a5 schema:name Springer Nature - SN SciGraph project
92 rdf:type schema:Organization
93 Nb54f97420a10489db04e26c8caff94e5 schema:isbn 978-981-16-2869-6
94 978-981-16-2870-2
95 schema:name Management of Pancreatic Cancer and Cholangiocarcinoma
96 rdf:type schema:Book
97 Nbe8c37f537d84b7cb4490edb5605fef3 rdf:first N50533a6c84764606ac88cae5cc0a1e8d
98 rdf:rest N8caf25440b04494a96d1b6db35457c43
99 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
100 schema:name Medical and Health Sciences
101 rdf:type schema:DefinedTerm
102 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
103 schema:name Oncology and Carcinogenesis
104 rdf:type schema:DefinedTerm
105 sg:person.0612301703.87 schema:affiliation grid-institutes:grid.258269.2
106 schema:familyName Saiura
107 schema:givenName Akio
108 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0612301703.87
109 rdf:type schema:Person
110 grid-institutes:grid.258269.2 schema:alternateName Department of Hepatobiliary-Pancreatic Surgery, Juntendo University School of Medicine, Hongo, Tokyo, Japan
111 schema:name Department of Hepatobiliary-Pancreatic Surgery, Juntendo University School of Medicine, Hongo, Tokyo, Japan
112 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...